HER2-Positive Colorectal Cancer Treatment with Targeted Inhibitors

Jump To Section

• HER2 in Colon Cancer
• HER2 Inhibitor Combination Therapy
• Personalized Treatment Approach
• First-Line Therapy Potential
• Future Treatment Development
• Full Transcript

HER2 in Colon Cancer

Some colorectal cancer tumors show amplification of the HER2 molecule. Dr. Hans-Joachim Schmoll, MD, explains that HER2 overexpression is a known target from breast and gastric cancer. This molecular alteration is present in approximately 5% of colon cancer patients. Identifying this subgroup is crucial for applying specific, effective targeted therapies.

HER2 Inhibitor Combination Therapy

The combination of trastuzumab (Herceptin) and lapatinib (Tykerb) has been extensively studied for HER2-positive colorectal cancer. Dr. Hans-Joachim Schmoll, MD, describes lapatinib as an oral tyrosine kinase inhibitor that targets HER2. This dual inhibition strategy proved highly effective as a last-line treatment. Remarkably, this targeted approach worked strongly without the need for classic chemotherapy.

Dr. Anton Titov, MD, discusses the significant implications of this finding. The success of this chemotherapy-free regimen in advanced disease settings is a major advancement. It offers a potentially less toxic and more effective option for a defined patient population.

Personalized Treatment Approach

Molecular profiling is revolutionizing colorectal cancer treatment. Dr. Hans-Joachim Schmoll, MD, emphasizes that treatment selection should be based on tumor molecular profile, not anatomical origin. Beyond the 5% with HER2 amplification, approximately 5% of patients have BRAF mutations and 50% have KRAS or NRAS mutations. Each molecular subgroup deserves a different, tailored treatment strategy.

Dr. Anton Titov, MD, agrees with this precision medicine approach. This represents a shift from broad, general treatments to targeted, molecular-based decisions. The goal is to match the right therapy to the right patient from the beginning.

First-Line Therapy Potential

The remarkable efficacy of HER2 inhibitors in last-line settings prompts investigation in first-line treatment. Dr. Hans-Joachim Schmoll, MD, states that trastuzumab and lapatinib will now be tested as first-line colon cancer therapy. Using the most effective targeted medications right at the start of treatment is critical for long-term survival. This approach is expected to be more effective and less toxic than classical chemotherapy.

Dr. Anton Titov, MD, highlights the importance of this progression in personalized cancer therapy. Initiating effective, targeted therapy immediately after diagnosis can significantly impact patient outcomes.

Future Treatment Development

While current medications are valuable, continued development of new targeted agents is essential. Dr. Hans-Joachim Schmoll, MD, stresses the need to use tumor mutations as targets for new drug development. The oncology community must continue to look for more targets to expand treatment options. This ensures that more patients can benefit from personalized, precision medicine approaches.

Dr. Anton Titov, MD, concludes the discussion by reinforcing the paradigm shift in cancer care. The future lies in biomarker-driven treatment selection, moving beyond organ-based classification to truly personalized medicine.

Full Transcript

Dr. Anton Titov, MD: Some colon cancer tumors show amplification of the HER2 molecule. When to use HER2 inhibitors in colon cancer treatment? Herceptin and lapatinib (Tykerb) are HER2 inhibitors for use in colorectal cancer treatment. How to combine HER2 inhibitors with other chemotherapy in colon cancer treatment?

Another colon cancer treatment target is HER2 overexpression.

Dr. Hans-Joachim Schmoll, MD: We know the HER2 gene from breast cancer and from gastric cancer. The trastuzumab antibody targets HER2 very well. Trastuzumab is also used with oral tyrosine kinase inhibitors in colon cancer treatments.

The combination of trastuzumab with lapatinib has been extensively studied. Lapatinib is an oral tyrosine kinase inhibitor of HER2. Treatment with trastuzumab and lapatinib without any additional chemotherapy was highly effective. It was used as last-line treatment in colon cancer patients who overexpressed HER2.

Trastuzumab and lapatinib will now be tested as first-line colon cancer treatment.

Dr. Anton Titov, MD: It worked very strongly without classic chemotherapy in last-line treatment of colon cancer. We hope it will work even better as first-line colon cancer therapy.

Dr. Hans-Joachim Schmoll, MD: So, this is personalized targeted therapy for 5% of the colon cancer patient population. Then we have another 5% of colon cancer patients with BRAF mutation. We have 50% with KRAS or NRAS mutation. We have more and more molecular subgroups of colon cancer patients.

Each subgroup deserves different treatment. Not only as last-line therapy, but as a first-line colon cancer therapy. We are changing from a broad and general treatment of colon cancer.

We are now taking molecular-based treatment decisions in colon cancer. Treatment combination is tailored for the molecular profile of the colon cancer tumor.

Dr. Anton Titov, MD: It is not tailored for the patient, like a real precision medicine treatment. As I said before, it is tailored for the molecular profile of the tumor.

Targeted HER2 colon cancer therapy is probably going to be more effective and less toxic than classical chemotherapy. It is a reason why we use these targeted treatments.

Dr. Hans-Joachim Schmoll, MD: Perhaps not at the beginning of colon cancer treatment. But using effective targeted therapy from the start of treatment is more relevant. It is more important for long-term survival of patients with colorectal cancer.

It is important to use the most effective medications right at the beginning of colon cancer treatment. To choose effective targeted therapy right after the diagnosis. Treatment based on the molecular profile of the tumor and genetic profile of the patient. Certainly, yes.

At the same time, we have to look for more targets for development of new medications. We can treat colon cancer with available medications, but we have to develop new medications. We have to use tumor mutations as targets for new medications.

Selection of therapy should be done based on the molecular profile of the tumor.

Dr. Anton Titov, MD: Selection of therapy should not be based on the anatomical originating organ of the tumor.

Dr. Hans-Joachim Schmoll, MD: Absolutely right. Colorectal cancer treatment with Herceptin and lapatinib (Tykerb) HER2 inhibitors. Herceptin and lapatinib in colon cancer treatment can be very effective.

Therapeutic dual inhibition of the HER2 pathway in metastatic colon cancer has to be used more often. SIRT in metastatic colorectal cancer also uses HER2 inhibitors. Lapatinib (Tykerb/Tyverb) is an oral tyrosine kinase inhibitor of HER2.

Trastuzumab (Herceptin) and lapatinib (Tykerb/Tyverb) can be tested as first-line colon cancer treatment. We are progressing in personalized colon cancer therapy.

Targeted HER2 colon cancer therapy is probably going to be more effective and less toxic than classical chemotherapy. Treatment with trastuzumab (Herceptin) and lapatinib did not require classical chemotherapy. Colon cancer patients who overexpressed HER2 were treated with Herceptin and lapatinib.

Leading colorectal cancer expert discusses HER2 inhibition in colon cancer therapy with Herceptin (trastuzumab) and lapatinib.